Project description:To assess the timing and scope of IRF4–dependent reprogramming in vivo, CTV-labeled IRF4–sufficient and –deficient B cells were transferred into mMT hosts. One day later, hosts were challenged with 50 mg LPS. Three days post-LPS challenge, transferred cells were recovered and sorted from divisions 0, 1, 3, 4, 5, and 6 as determined by CTV dilution for ATAC–seq.
Project description:To assess the timing and scope of IRF4–dependent reprogramming in vivo, CTV-labeled IRF4–sufficient and –deficient B cells were transferred into mMT hosts. One day later, hosts were challenged with 50 mg LPS. Three days post-LPS challenge, transferred cells were recovered and sorted from divisions 0, 1, 3, 4, 5, and 6 as determined by CTV dilution for RNA–seq.
Project description:To determine the impact of a low Mg(2+)/pH defined growth medium (MgM) on the proteome of Salmonella enterica serotype Typhimurium, researchers cultured S. Typhimurium cells in the medium under two different conditions termed MgM Shock and MgM Dilution and then comparatively analyzed the bacterial cells harvested from these conditions by a global proteomic approach.
Project description:Pyruvate fermentation pathway and energetics of Desulfovibrio alaskensis strain G20 under syntrophic coculture and fermentative monoculture conditions Expression data for Desulfovibrio alaskensis strain G20 grown in chemostats on pyruvate under respiratory conditions (sulfate-limited and pyruvate-limited monoculture, dilution rate 0.047 and 0.027 h-1), fermentative conditions (monoculture, dilution rate 0.036 h-1), and syntrophic conditions (coculture with Methanococcus maripaludis or Methanospirillum hungatei, dilution rate of 0.047 and 0.027 h-1)
Project description:Interventions: Drug : Study design &Intervention schedule
This study is a multicenter, phase 2, single arm study. Individual investigators are allowed to choose 2nd line chemotherapy agents,bevacizumab, cetuximab,aflibercept depending on their decision.
GVl001 is injected intradermally on days 1, 3, 5 and 8 of the first cycle of 2nd line chemotherapy with a dose of 0.56 mg, and then injected on day 1 of subsequent chemotherapy. GV1001 should be injected intradermally in the lower abdomen with 0.2 mL of diluted to 0.30 mL of 0.9% normal saline (2.8 mg/mL), administered immediately after dilution (at least within 6 hours after dilution).
This treatment is repeated every 2 weeks until the discontinuation of treatment due to the patients’ request, the toxicity, or the progress of the disease.
Primary outcome(s): Disease control rate
| 2511784 | ecrin-mdr-crc
Project description:Antarctic biological sample data MG-DA
Project description:Cells have been collected by limited dilution and mRNA from 3 consequtive passages of cells cultured in Dulbecco’s modified Eagle’s medium (DMEM Dutscher L0104-500) containing 4.5 g/L glucose, L-glutamine, sodium pyruvate supplemented with 10% of inactivated fetal bovine serum (FBS, Dutscher S1510-500), penicillin (10 000 U/mL), streptomycin (10 mg/mL) (Dutscher P06-07100) were used for RNA seq analysis.